New products « Science and Enterprise

Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds

By Alan, on June 7th, 2023%

A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds. . . . → Read More: Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds

Vaccine Patch Shown Safe, Induces Immune Response

By Alan, on June 6th, 2023%

Initial results from a clinical trial show a patch device delivering a Covid-19 vaccine is well tolerated by recipients and triggers a measurable immune response. . . . → Read More: Vaccine Patch Shown Safe, Induces Immune Response

Infographic – VR, AR Yet to Reach Critical Mass

By Alan, on June 3rd, 2023%

Bar chart: VR and AR adoption through 2027

While applications of VR and AR technologies can seem compelling, the numbers of people actually using these systems remain relatively small. . . . → Read More: Infographic – VR, AR Yet to Reach Critical Mass

Primate Genome A.I. Model IDs Human Disease Variants

By Alan, on June 2nd, 2023%

A genomic systems company created an artificial intelligence algorithm from primate genomic data that identifies possible disease-causing mutations in humans. . . . → Read More: Primate Genome A.I. Model IDs Human Disease Variants

Clinical Trial Begins for Peanut Allergy Treatment

By Alan, on June 1st, 2023%

A clinical trial is underway testing an experimental therapy for peanut allergy that its developer says trains the immune system without using peanut proteins. . . . → Read More: Clinical Trial Begins for Peanut Allergy Treatment

Crispr Therapy Shown to Reduce Harmful Gut Microbes

By Alan, on May 31st, 2023%

A clinical trial shows an oral therapy with engineered viruses delivers precise gene-edited payloads to reduce E. coli communities in the gut with no serious adverse effects. . . . → Read More: Crispr Therapy Shown to Reduce Harmful Gut Microbes

Precision T-Cell Solid Tumor Therapy Trial Underway

By Alan, on May 30th, 2023%

A clinical trial has begun testing a treatment for solid tumor cancers using engineered T-cells with proteins to attack specific tumor cells, but also avoid healthy cells. . . . → Read More: Precision T-Cell Solid Tumor Therapy Trial Underway

AI-Designed Cancer Vaccine Shown to Act Against Melanoma

By Alan, on May 26th, 2023%

Results of a small clinical trial show most patients with melanoma receiving a personalized therapeutic vaccine with an approved immunotherapy reduced at least some of their tumors. . . . → Read More: AI-Designed Cancer Vaccine Shown to Act Against Melanoma

Low-Dose Oral Film Reduces Mental Disorder Agitation

By Alan, on May 25th, 2023%

Interim results from a clinical trial show a drug given as a dissolvable oral film in a lower dose reduces agitation in people with bipolar disorder and schizophrenia. . . . → Read More: Low-Dose Oral Film Reduces Mental Disorder Agitation

Safer Forms of Psilocybin Assessed in Preclinical Study

By Alan, on May 22nd, 2023%

A biotechnology company says it identified engineered precursors of a psychedelic compound that in lab animals produce safe and intended therapeutic effects. . . . → Read More: Safer Forms of Psilocybin Assessed in Preclinical Study

Subscribe for email alerts

Donate to Science & Enterprise

Like us on Facebook

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Specials

Guest Posts

Please share Science & Enterprise